JAK/TYK2

Steroids, Not JAKi, Are the Real Infection Risk Dr. David Liew reporting at EULAR 2025 in Barcelona, Spain. https://t.co/rLpyo1UNjd https://t.co/bDfdLTEM1N

Links:

Dr. John Cush @RheumNow( View Tweet )
Seronegative Arthritis Breakthroughs Dr. Janet Pope discusses abstracts POS0015, "Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors" and POS0016, "Characterization of ORKA-002, a Novel https://t.co/7nmOWw11lb
Dr. John Cush @RheumNow( View Tweet )
eular

EULAR 2025 – Day 4 Report

Jack Cush, MD

Saturday was the final day of EULAR, and included several lectures, but mostly late breaking abstracts and new EULAR guidelines - notably on Rheumatoid Arthritis and another on Interstitial Lung disease in connective tissue disorders. My favorite presentations included the following.

Read Article
RA Care Should be Guided by Need—Not Age Dr. Jiha Lee reports on abstract POS0627, "Examination of Clinical Outcomes by Treatment Duration of Biologics and JAK inhibitors in Nonagenarian Rheumatoid Arthritis," at EULAR 2025 in Barcelona, Spain. https://t.co/zKHXZSVLJy https://t.co/w6CkRy2yIA

Links:

Dr. John Cush @RheumNow( View Tweet )
PsA.Hands_.jpg

From Domains to Decisions: Personalizing PsA Care with Data

Jiha Lee, MD

At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; it’s about understanding the unique constellation of domains, comorbidities,

Read Article
POETYK PsA-1 Deucravacitinib TYK2i RCT Ph 3 ACR 20 DEU 54% vs. 34% PBO wk 16 ACR 50 DEU 23% vs. 14% PBO also significant diff for HAQ-DI PASI 75 SF-36 PCS and MDA Less Rx progression @RheumNow #EULAR2025 LB0001 https://t.co/oRLlHwI4Bh

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Deucravacitinib, the first oral TYK2 inhibitor, delivers in PsA: ✅ ACR20: 54% vs 34% (placebo) ✅ Skin, joints, fatigue, QoL 📉 Post hoc: less radiographic progression No new safety signals at W16. LB0001 @RheumNow #EULAR2025

Jiha Lee @JihaRheum( View Tweet )

📊 In POETYK PsA-1, deucravacitinib (TYK2i) significantly improved ACR20 at W16 (54% vs 34% placebo) in bDMARD-naive PsA. Also improved QoL, skin, and MSK outcomes. Post hoc: slowed radiographic progression. Well tolerated & no new safety signals @RheumNow #EULAR2025 #LB0001

Mrinalini Dey @DrMiniDey( View Tweet )

✅Exciting results from POETYK PsA-1: -Deucravacitinib (TYK2i) in PsA -ACR 20 was achieved in significantly more patients treated with deucravacitinib vs placebo at W16 (54.2% vs 34.1%; P < 0.0001), with similar results for ACR 50 and ACR 70 -Also met 2dary endpoints. -Post hoc https://t.co/S4DhovMCma

Links:

Adela Castro @AdelaCastro222( View Tweet )
Tofacitinib vs biologics in PsA: 📍MI/stroke ✅ similar 📍Serious infection ✅ similar 📍Malignancy ✅ similar 📍VTE ❌ higher vs TNFi (aHR 0.26) Large US claims study (n=48k) Abstract POS0296 @RheumNow #EULAR2025

Jiha Lee @JihaRheum( View Tweet )

EULAR,poster

EULAR 2025 – Day 2 Report

Jack Cush, MD

Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few

Read Article
#infections in #JAKi @drdavidliew #JAKi sl ⬆️ infection risk vs #TNFi ⬆️HZ w JAKi JAKi same risk w #latent #TB #LTBI and new TB ⬇️in JAKi v bDMARDs He didn’t discuss TYK2i Reassuring - risk⬇️ over time for infection @RheumNow #EULAR2025 @eular_org JAKi & infection https://t.co/KVsY2gXVkQ

Links:

Janet Pope @Janetbirdope( View Tweet )
Management of HLH/MAS and modes of action of advanced therapies Jessica Manson @RheumNow #EULAR2025 https://t.co/Op3u53ZXeK

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
JAKi: expanding RMD indications—but important safety concerns to consider ⚠️ Cancer: Neutral vs MTX/placebo, ↑ risk vs TNF ⚠️ Infection: ↑ with age, disease activity & GC use—not uniformly higher with JAKi 🗣️ Patients rank infection risk as top concern @rheumnow #EULAR2025 https://t.co/RJRDWQjqNC

Links:

Jiha Lee @JihaRheum( View Tweet )
Age & dose ⬆️ infections in JAKi Not all JAKi are created w equal risk ⁦@RheumNow⁩ ⁦@eular_org⁩ #EULAR2015 ⁦@drdavidliew⁩ #JAKi & #infection https://t.co/F7zLUBuzJR

Links:

Janet Pope @Janetbirdope( View Tweet )
#Cancer is not ⬆️in JAKi vs #bDMARDs in #rheumatoid #arthritis When adjusted for #confounders #JAKPOT data Now you see it (unadjusted ⬆️risk) Now you don’t (adjusted =#malignancy) JAKi vs bDMARDs in RA EULAR2025 @RheumNow @eular_org #JAK it out! new perspective on JAKi https://t.co/wCQ3dHNAVa

Links:

Janet Pope @Janetbirdope( View Tweet )
POS0150: From 12 RA registries, JAKi starts fell by ~13% after FDA safety alerts. Tofa & bari took biggest hits; upa growth slowed but offset losses. Real-world prescribing adapts—but doesn’t abandon. @RheumNow #EULAR2025 https://t.co/QZ5haW2vhX

Links:

Jiha Lee @JihaRheum( View Tweet )
Fascinating to see JAKi uptake in European JAK-pot centres - tofa was already on the decline pre-ORAL Surveillance - JAKi use (driven by upadacitinib) continues to grow, although maybe it’s slowed Hopefully rational JAKi has its place #EULAR2025 POS0150 @RheumNow https://t.co/XRyHJVw821

Links:

David Liew @drdavidliew( View Tweet )
New dual-action RA drug? OP0193: CPL’116 targets both JAK & ROCK. In 12-wk RCT, highest dose improved DAS28-CRP, joint counts & pain, with clean labs. Is this a future option for RA-ILD or patients with comorbid CVD risk? #EULAR2025 @RheumNow

Jiha Lee @JihaRheum( View Tweet )

Ph 2 RCT CPL'116 dual inhibition JAK/ROCK 106 MTX IR pts wk12 primary endpoint met (DAS28-CRP decrease) in 240mg arm vs. PBO 75% >= AEs, SAE 2: 1 MI, 1 bladder cancer Authors suggest absence of lipids/LFTs disruption compared to other JAKs Ph3 is awaited!! #OP0193 #EULAR2025 https://t.co/TnnM410LfM

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Real-world study on dual bDMARD plus JAKi or TYK2i combinations in refractory PsA. 22 PsA patients on dual bDMARD + JAKi/TYK2i: •Most common: IL-17i + TYK2i •Total exposure: 8.5–10.5 pt-years •Only mild URIs/stomatitis •Clinical improvements seen in joint/skin domains https://t.co/waDReDqSDE

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Hepcidin detected in synovial membrane and fluid in RA, PsA, and OA. Monocytes were the main source. IL-6, IL-10, IL-17, M-CSF induced hepcidin via JAK-STAT pathway. Hepcidin reduced osteoclastogenesis but correlated with synovial neutrophils and CXCL1 induction. Functional dual https://t.co/ZjUtTYPre8

Links:

Antoni Chan MD (Prof) @synovialjoints( View Tweet )
Phase 3 of POETYK-PsA-2: -Deucravacitinib (oral TyK2i) met the primary endpoint of ACR20 at week 16 and was superior to placebo in multiple PsA domains. -Clinical efficacy maintained until week 52. -No major safety signals reported. -Notably high placebo response rates. Abstract

Adela Castro @AdelaCastro222( View Tweet )

PSA2L.jpg

Combination treatments in Psoriatic Arthritis

Antoni Chan, MD, PhD

Despite the advances in the treatment of PsA with biologic (bDMARD) and targeted synthetic (tsDMARD), less than half of patients with this condition achieved remission or low disease activity. Combination DMARD treatment is often used in order to achieve remission or minimal disease activity.

Read Article
❓️How effective and safe is it to combine bDMARDs and tsDMARDS (i.e. TNFi/ IL17i + JAKi/TYKi) in #psoriatic_arthritis? 🅰️ Reassuring data from a case-series study presented by Andre Lucas Ribeiro #EULAR2025 OP0090 @RheumNow #Strategy https://t.co/W8fuzSgxbJ

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )

Recent Blogs

JAKi for PMR: Safe, or a Concern for Older Adults?

David Liew, FRACP
Dr. David Liew
JAK inhibitors obviously have dominated a lot of the discussion in our therapeutic landscape over the last couple of years. What about their use in polymyalgia rheumatica? Let's consider. Read Post

Infections Rheums Should Worry About

Cassandra Calabrese, DO
TB.EMimage.CDC_.jpg
With the increasing development and use of new biologics and oral targeted therapies to treat RA and other immune mediated inflammatory diseases, an awareness of infection risk and prevention has become of increasing interest as well. While our patients may be susceptible to many different types of infections depending on immunosuppressive regimen, age and co-morbidities, I’ll highlight a few of the “usual suspects”. Read Post
×